Tumor FAK Orchestrates Immunosuppression in Ovarian Cancer via the CD155/TIGIT Axis

Using an aggressive mouse ovarian tumor model, scientists found that combined oral FAK inhibitor plus function-blocking TIGIT antibody immunotherapy reduced tumor burden, prolonged mouse survival, and led to immune cell activation and tertiary lymphoid structure formation, hallmarks of an antitumor immune response.